IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.40 USD
-0.02 (-4.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $0.39 -0.01 (-2.28%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IGC 0.40 -0.02(-4.50%)
Will IGC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IGC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGC
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
IGC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Other News for IGC
MACD Bullish Signal Line Cross appears for IGC after 1.44% move
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
20 Day Moving Average Support appears for IGC after 2.69% move
Is IGC primed for upward momentum? Crossed Above 20 Day Moving Average shows up after rising 1.95%
IGC's Latest Discovery in Alzheimer's Treatment Shows Promise